HR Execs on the Move

Savient

www.savient.com

 
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA? (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.savient.com
  • 14 Center Ln
    East Brunswick, NJ USA '08816
  • Phone: 732.418.9300

Executives

Name Title Contact Details

Similar Companies

Flare Capital

Flare Capital Partners invests and specializes exclusively in the healthcare technology sector. Working side-by-side, Flare Capital parlays strengths in business and medicine into action that supports entrepreneurs who provide innovative solutions and strive to be market leaders.

Evernow

Menopause treatment custom to you.

Insightra Medical

Insightra Medical is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Compass Professional Health Services

Compass Professional Health Services is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.